Current Issue : July-September Volume : 2026 Issue Number : 3 Articles : 1 Articles
The improved clarity and focus ensure readers immediately grasp both the therapeutic importance of these hybrids and the robust scientific methodology supporting their discovery. A novel benzoimidazole-based 1,3,4-oxadiazole and 1,2,3-triazoles were synthesized and characterized by NMR (1H/13C) and mass spectroscopy. Biological testing confirmed that 6j showed excellent antibacterial activity with excellent ZI values of 34.48±1.04 mm against E. coli and 31.71±2.01 mm against B. cereus. Remarkably, compound 6i stood out for its strong antibacterial action, giving a 36.90±0.88 mm inhibition zone against S. aureus, which is higher than standard antibacterial drug moxifloxacin (ZI=36.01±0.93 mm). It also showed high activity against Gram-negative bacteria, with a 36.20±0.37 mm inhibition zone against E. coli. Docking studies also showed that the active ligands 6a, 6i and 6j had the best interaction with the S. aureus DNA gyrase enzyme (ΔG=−5.46 to −7.65 kcal. mol−1), mainly because of its high heteroatom content, which supported strong hydrogen bonding and hydrophobic interactions. ADMET profiling, encompassing toxicity prediction via SwissADME, was performed to evaluate drug-likeness and developability. Overall, these findings suggest that benzoimidazole-based dual heterocyclic derivatives, especially 6i is promising candidates for developing new broad-spectrum antimicrobial agents....
Loading....